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Abstract 
Objectives 
To investigate the words and descriptions used by haematology healthcare professionals (HCPs) to 
describe monoclonal gammopathy of undetermined significance (MGUS) to their patients.  
Methods 
A cross-sectional survey of haematology HCPs attending an annual haematology conference was 
undertaken. Content analysis was applied to the returned qualitative responses. 
Results 
In total, 55 people, many of whom were doctors (n=32; 58.2%) responded.  The majority of 
respondents reported using simple terminology such as ‘abnormal protein’ to describe MGUS to 
their patients.  Some reported using analogies that the patient was more likely to be familiar with, 
such as comparing a paraprotein to the finding of a mole or lump.  Education level, age and cognitive 
ability were cited as important factors in deciding how and if information was relayed to patients. 
Many respondents supported frequent follow-up and the transfer of low risk MGUS patients to 
primary care.  However, several highlighted a lack of awareness and understanding of MGUS outside 
of haematology, particularly within primary care.  Only 41.8% of respondents reported providing all 
of their patients with an information leaflet.   
Conclusions 
With an ageing population, it is important to consider management strategies for MGUS patients.   
Our findings will assist those in making these arrangements. 
 
Keywords: MGUS, healthcare professionals, haematology, myeloma, communication aids, 
management (follow-up) 
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KEY FINDINGS & RECOMMENDATIONS 
 Haematology healthcare professionals often use simplistic terminology to describe MGUS to 
their patients  
 Healthcare professionals require easy access to patient-friendly information leaflets 
 Increased support for GPs in diagnosing and following-up MGUS patients may be required 
and could be supported through the development of guidelines which provide clear 
instructions on how to manage MGUS patients 
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Introduction 
The most prevalent of the plasma cell disorders, monoclonal gammopathy of undetermined  
significance (MGUS), has been shown in two independent studies to consistently precede multiple 
myeloma (MM) (1,2), an incurable malignancy (3).  Clinically MGUS is defined using the International 
Myeloma Working Group definition as <30g/l of serum monoclonal (M) protein in the absence of 
MM, <10% plasma cell infiltration in the bone marrow and absence of end organ damage (CRAB 
criteria – hypercalcaemia, renal insufficiency, anaemia and bone lesions)(4).   The annual risk of 
progression to MM and associated malignancies is 0.5-1%, with risk remaining elevated beyond 25 
years of observation(5–7).  Given the risk of malignant transformation and increased association 
with medical disorders such as osteoporosis/osteopenia, fractures (particularly vertebral 
compression fractures), peripheral neuropathy and deep vein thrombosis(8–11) it is recommended 
that MGUS patients are monitored indefinitely(12).   
 
MGUS is asymptomatic and for the majority of patients, diagnosis will be incidental following routine 
bloodwork or diagnostic workup.  From ongoing research, the study team are aware that the words 
and descriptions used by patients to describe their MGUS diagnosis vary. This is in line with reports 
for other pre-malignant conditions, such as ductal carcinoma-in-situ, where patients report diverse 
terminology used by healthcare professionals including ‘breast cancer’, ‘early cancer’, ‘in situ’, ‘pre-
malignant’, ‘ductal carcinoma in situ’, ‘DCIS’, ‘abnormal cells’, ‘non-invasive’ and ‘pre-cancer(ous)’ 
(13–15).  For patients diagnosed with premalignant conditions, uncertainty about the condition and 
potential progression to cancer can resonate (13,16,17).  For this reason healthcare professionals 
may choose simpler terminology to describe the condition at the point of diagnosis and follow-up 
care.  How pre-malignant diagnoses are communicated to patients is of paramount importance to 
reduce the psychosocial impact of diagnosis (13,18,19). Patients with haematological malignancies 
report varied needs for information on the disease, treatment and prognosis with tailored 
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communication to the patient advocated(20).  Likewise, provision of accurate and timely information 
for MGUS patients is equally important.  To date, we are unaware of any published literature 
describing how a diagnosis of MGUS is communicated to patients, the terminology used or the 
provision of communication aids(21).  We report here on the words and descriptions used by 
haematology healthcare professionals to describe MGUS to their patients and their views towards 
follow-up.   
 
 
Methods 
A cross-sectional survey of healthcare professionals attending the annual Haematology Association 
of Ireland meeting on 14-15th October 2016 was undertaken.  This meeting is attended by a wide 
range of specialities interested in haematology including doctors, nurses, allied healthcare 
professionals, scientists and students from both Northern Ireland (UK) and the Republic of Ireland.  
Ethical approval from Queen’s University Belfast School of Medicine, Dentistry and Biomedical 
Sciences Research Ethics Committee (Ref: 16.47v1.0) was obtained.   
 
Survey 
The study team developed a short survey consisting of nine questions. Four questions were designed 
to capture basic information on the respondents’ experience with MGUS patients [current job role, 
region of practice (Northern Ireland vs Republic of Ireland), frequency of seeing MGUS patients and 
number of MGUS patients on clinic lists].  The remaining questions explored the words and 
descriptions used by healthcare professionals on the island of Ireland to describe MGUS to their 
patients. Questions about the use of information leaflets and follow-up recommendations were also 
included. Each survey was labelled with a unique number and all survey responses were anonymous.   
 
 6 
 
All attendees were provided with the survey together with the study poster and information booklet 
within their meeting programme.  Only healthcare professionals (doctors, nurses and allied 
healthcare professionals) were instructed to complete the survey.  To increase awareness of the 
study, the study poster was displayed on the presentation screen at the end of the oral presentation 
sessions and posters were also displayed throughout the main meeting rooms.  Participants were 
asked to return the completed surveys to the boxes labelled ‘MGUS study’ located in strategic 
locations throughout the meeting venue.  Respondents were entered into a draw for an iPad mini. 
 
Data Analysis  
The returned survey responses were entered into Microsoft Excel.  Analysis was performed in Stata 
version 14. Chi-square and Fisher’s exact tests were used to compare respondent demographics 
where appropriate.  The data was analysed to document the words and descriptions used by 
healthcare professionals to describe MGUS to their patients.  Responses to the open-ended 
questions were reviewed and analysed using content analysis(22).   
 
 
Results 
In total, 55 people responded to the survey, Table 1.  Of the 55 respondents, 74.5% (n=41) worked 
within the Republic of Ireland, 23.6% (n=13) in a United Kingdom region (Northern Ireland) and 1.8% 
(n=1) elsewhere.  The majority of respondents were doctors (n=32; 58.2%) with consultant 
haematologists comprising half of this population (n=16).  Of the nursing attendees (n=21), 57.1% 
(n=12) were clinical nurse specialists.  There was also one allied healthcare professional.  When 
investigated by region, consultant haematologists were the highest represented group in the Rep. of 
Ireland (31.7%) while haematology nurses comprised 46.2% of the Northern Ireland respondents.  
The majority of respondents reported diagnosing/following-up/taking care of MGUS patients on a 
 7 
 
weekly basis (n=27; 49.1%).   MGUS clinic lists tended to be small consisting of 0-50 MGUS patients 
(n=23; 41.8%) however, 7.3% (n=4) of respondents had more than 200 MGUS patients on their clinic 
lists. 
 
Describing MGUS to patients. 
When asked in an open-ended question, “what words do you use to describe MGUS to patients 
when first diagnosed?”, the majority (60%) of respondents favoured simple language such as the 
presence of an ‘abnormal protein in the blood’ requiring ongoing monitoring, Table 2. Only 38.2% 
(n=21) of respondents included the terms premalignant, precancer or cancer (example, multiple 
myeloma, blood/bone marrow cancer or haematological malignancy) within their responses to this 
question.  To aid understanding, some reported using analogies that the patient was more likely to 
be familiar with such as "like a mole we need to watch" and “finding a paraprotein is a bit like finding 
a 'lump' and needing to investigate further whether benign or malignant”.  Signs/symptoms and/or 
the need to monitor bloods, kidneys and bones for future problems were specifically mentioned by 
18.2% (n=10) respondents.  Only 7.3% (n=4) of respondents, all of whom were doctors (n=3 
consultants and n=1 registrar) reported telling patients of the relationship between MGUS 
prevalence and advancing age.  Overall, respondents were keen to reassure their patients that 
MGUS was unlikely to cause any harm, but ongoing follow-up/monitoring is needed in case of 
changes/symptoms requiring treatment. 
 
Telling patients they have MGUS. 
Excluding those (n=7) who stated that informing patients of their diagnosis was not applicable to 
their job role (specialist nurse/nurse/allied healthcare professional), the majority of respondents 
(79.2%; n=38 out of 48) reported telling ‘all patients’ that they had MGUS using either the term 
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‘MGUS’ or ‘monoclonal gammopathy of undetermined/uncertain significance’. An additional 20.8% 
(n=10) stated that they only told ‘some patients’.  While telling patients provided an opportunity for 
ownership and education, others stated educational level, age and cognitive ability were important 
factors in deciding how to relay the information, Table 2.  Often in these situations, respondents 
chose to use simpler terms such as ‘abnormal protein’ to convey the message.   
 
Telling patients of their risk of progression 
In terms of informing patients of their risk of progression to a haematological malignancy, 69.1% 
(n=38 out of 55) reported telling ‘all patients’ while 16.4% (n=9) reported telling only ‘some 
patients’.  Respondents who stated ‘No’ or wrote ‘unsure’ in response to this question (n=8), came 
from nursing/allied healthcare professional backgrounds (n=2 specialist nurses, n=5 nurses and n=1 
allied healthcare professional).  One specialist nurse confirmed in free text that they did not tell their 
patients the risk of myeloma, while the majority felt that communication of risk was the doctor’s 
duty.  Those who reported telling ‘all patients’ were keen to highlight the low risk of progression and 
referred to published estimates on MGUS progression/risk stratification from the Mayo Clinic 
studies, Table 2.  Others felt that patients needed to be aware of the risk as a rationale for the 
ongoing monitoring either by their haematology team or GP.  The importance of informing patients 
on risk of progression to myeloma was highlighted by one respondent who said it would be better to 
do so in case the patient looked MGUS up on the Internet, Table 2.  Another respondent stated that 
they avoid using the terms progression to ‘cancer’ or ‘malignancy’ and instead describe progression 
to a ‘blood condition’ unless the patient enquires further, in which case progression to ‘a type of 
blood cancer’ is discussed.  Being elderly/frail were cited as reasons to avoid telling patients of their 
risk of progression as it was stated that this could cause anxiety or distress to the patient. One 
respondent stated that risk of progression would only be disclosed to such patients if an increase in 
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paraprotein was detected in follow-up.  One consultant stated that they told their patients of the 
risk of progression ‘less than I probably should’.  
 
Information leaflet 
Overall, 41.8% (n=23 out of 55) of respondents reported providing all patients with a MGUS 
information leaflet.   An additional 27.3% (n=15) reported providing an information leaflet if asked 
by the patient, while 23.6% (n=13) did not give out information leaflets. The majority of nurses 
(61.9%) reported providing information leaflets to all of their patients compared to 31.3% of doctors, 
while healthcare professionals in Northern Ireland appeared more likely than those in the Rep. of 
Ireland to give an information leaflet to all patients (53.8% vs 39%).   Although no free text option 
was provided for this question, some respondents provided additional comments stating that some 
patients declined information leaflets, while others highlighted the lack of appropriate information 
leaflets and difficulties accessing these resources. 
  
Follow-up 
Excluding the three individuals from nursing backgrounds who earlier in the survey stated that the 
decision-making process was not part of their job role, more than half of the respondents (53.8%, 
n=28 out of 52) reported that all MGUS patients should be reviewed frequently; 32.7% (n=17) 
reported that follow-up should be aimed at patients considered to be at intermediate/high risk of 
progressing while 25% (n=13) reported that follow-up should involve primary care. Of the 52 
respondents, 78.8% (n=41) provided additional information to this question.  Many agreed that a 
combined approach to follow-up was favourable with low risk MGUS patients being followed-up by 
their GP (if willing) and the intermediate/high risk patients being reviewed frequently by their 
haematology healthcare team, Table 2.  The frequency of follow-up suggested by respondents varied 
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with some suggesting that it should be based on risk of progression while others reported following-
up patients at varying intervals such as 3-4 months, 6 months or annually.  Some felt that follow-up 
could be nurse-led and via telephone clinics as ‘clinic appointments create unnecessary stress to 
otherwise well patients’.  Those advocating for follow-up in primary care suggested that GPs should 
be supported in this process through the provision of clear instructions on follow-up procedures and 
the signs and symptoms to look out for. 
 
Awareness of MGUS 
Of the 55 respondents, 29.1% (n=16) provided additional comments they believed would be of 
interest to the study team.  The predominant focus of these comments concerned the lack of 
awareness and understanding of MGUS by healthcare professionals outside haematology which was 
described as being ‘generally poor’.  Particular reference was made to GPs who were highlighted as 
needing support to avoid over-diagnosing and over-referring patients to haematology with abnormal 
serum protein electrophoresis results.  Recognising detection of a paraprotein can ‘cause 
unnecessary anxiety’, it was suggested that guidelines are needed to assist healthcare professionals 
in deciding the appropriate time to test for paraproteins.  Similarly, it was highlighted that MGUS 
patients are often not well-informed and can find it difficult to comprehend MGUS, ‘often as much 
as I try to explain they still don't understand.’  As with other patients on watch and wait surveillance, 
one respondent stated that MGUS patients represent ‘a hugely neglected cohort of patients from a 
nursing input’ and that patients could benefit from access to a patient-friendly information leaflet. 
 
Discussion 
The findings of this study suggest that while the majority of MGUS patients are informed of their 
diagnosis, there may be situations where haematology healthcare professionals decide that 
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alternative terminology is necessary.  Age, education and cognitive ability were cited as the main 
reasons for withholding information about the condition and/or the risk of progression to myeloma 
and associated malignancies.  The findings of this study have implications for patients and healthcare 
professionals alike. 
 
The main strength of our study was that we were able to capture the views of a range of healthcare 
professionals within haematology from two different healthcare systems.  As a region of the United 
Kingdom, Northern Ireland uses the National Healthcare System (NHS) which provides free 
healthcare for all.  In contrast, the Republic of Ireland currently operates a two-tier healthcare 
system which affords preferential access to those with private health insurance (approximately 45% 
of the population)(23).  Despite these differences, similar responses to the survey were expressed by 
healthcare professionals in both countries suggesting our findings may be generalizable to other 
regions. Within this survey, the majority of respondents supported frequent review of MGUS 
patients with follow-up of low risk patients within primary care/community settings. Outreach 
haematology services for MGUS patients, involving specialist nurse-led community monitoring 
programmes, have been shown to be effective and improve patient satisfaction in the UK(24).  
However, while transferring/sharing of services between primary and secondary care may reduce 
haematology service burden, the economic impact to patients by replacing free outpatient visits, as 
provided in the Republic of Ireland, with costly GP visits for those <70 years of age who are not 
eligible for free primary care visits(23) should not be overlooked.  
 
Despite advocating for MGUS follow-up within primary care, several respondents reported a general 
lack of awareness and knowledge of MGUS by healthcare providers outside haematology.  As MGUS 
review moves increasingly towards primary care, the challenge is for haematology specialists to 
work alongside GPs to ensure appropriate care pathways, adhering to the published guidelines are in 
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place (25–27). Development of standardised discharge letters for MGUS patients with clear 
instructions on follow-up procedures and symptoms/signs of progression for primary care providers 
warrants further assessment.   
  
Several respondents highlighted that the detection of a paraprotein can lead to unnecessary stress 
and anxiety in patients.  While several studies have reported increased anxiety and distress in 
patients with premalignant conditions (28,29), lack of appropriate information at diagnosis and 
follow-up is consistently reported (13,18,19).  Provision of an information leaflet at the point of 
diagnosis is recommended by the UK Myeloma Forum and Nordic Myeloma Study Group(26) and 
may help reduce psychological distress experienced by patients(30).  However, within the present 
study, just over 40% of respondents reported providing all of their MGUS patients with an 
information leaflet despite acknowledging that patients are often confused by their diagnosis and 
are generally not well-informed.  Many respondents cited that information leaflets were not 
available to them and highlighted the need for development of an appropriate information leaflet.  
Currently, MGUS patient information leaflets are freely available on the internet from cancer charity 
websites including Myeloma UK and Macmillan.  It is important that all healthcare professionals are 
made aware of these underutilised resources and that arrangements are put in place to make these 
valuable resources available to patients. While restricting the survey to attendees of the 
Haematology Association of Ireland meeting may have limited the generalisability of the findings, it 
is still the largest haematology meeting on the island of Ireland and attended by a wide spectrum of 
healthcare professionals with different roles and experience. 
 
In conclusion, this survey of haematology healthcare professionals has highlighted a number of 
important issues for patients and healthcare professionals.  Moving forward, it is imperative that 
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guidelines are developed to assist healthcare professionals outside haematology, particularly GPs, in 
managing MGUS patients.    
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Table 1. Summary of survey responses 
* Numbers do not equal to 100% as respondents ticked multiple options which have been counted 
separately 
 All 
respondents 
(n=55) 
Rep. of Ireland 
respondents 
(n=41) 
Northern Ireland 
respondents 
(n=13) 
p-value 
Job 
Consultant 
Registrar 
Foundation doctor 
Specialist Nurse 
Nurse 
Allied Healthcare professional 
Other 
 
16 (29.1) 
12 (21.8) 
4 (7.3) 
12 (21.8) 
9 (16.4) 
1 (1.8) 
1 (1.8) 
 
13 (31.7) 
11 (26.8) 
4 (9.8) 
9 (22) 
3 (7.3) 
1 (2.4) 
0 
 
3 (23.1) 
1 (7.7) 
0 
3 (23.1) 
6 (46.2) 
0 
0 
0.04 
Frequency 
Daily 
Weekly 
Monthly 
Never 
Prefer not to say 
 
7 (12.7) 
27 (49.1) 
12 (21.8) 
6 (10.9) 
3 (5.5) 
 
6 (14.6) 
22 (53.7) 
7 (17.1) 
4 (9.8) 
2 (4.9) 
 
1 (7.7) 
5 (38.5) 
4 (30.8) 
2 (15.4) 
1 (7.7) 
 
0.66 
Number of patients 
0-50 
51-100 
101-200 
201+ 
Prefer not to say/missing 
 
23 (41.8) 
14 (25.5) 
5 (9.1) 
4 (7.3) 
9 (16.4) 
 
16 (39) 
13 (31.7) 
4 (9.8) 
3 (7.3) 
5 (12.2) 
 
7 (53.9) 
1 (7.7) 
1 (7.7) 
1 (7.7) 
3 (23.1) 
 
0.39 
Do you tell patients they have 
MGUS? 
Yes, all patients 
Yes, some patients 
No 
Missing/other 
 
 
38 (69.1) 
9 (16.4) 
6 (10.9) 
2 (3.6) 
 
 
31 (75.6) 
6 (14.6) 
3 (7.3) 
1 (2.4) 
 
 
7 (53.9) 
2 (15.4) 
3 (23.1) 
1 (7.7) 
 
0.20 
Do you tell MGUS patients about 
risk of progression? 
Yes, all patients 
Yes, some patients 
No 
Missing/other  
 
 
38 (69.1) 
9 (16.4) 
7 (12.7) 
1 (1.8) 
 
 
29 (70.7) 
8 (19.5) 
4 (9.8) 
0 
 
 
8 (61.5) 
1 (7.7) 
3 (23.1) 
1 (7.7) 
 
0.15 
Do you give MGUS patients 
information leaflet? 
Yes, all the time 
Only if the patient asks 
Never 
Missing/other 
 
 
23 (41.8) 
15 (27.3) 
13 (23.6) 
4 (7.3) 
 
 
16 (39) 
13 (31.7) 
9 (22) 
3 (7.3) 
 
 
7 (53.8) 
1 (7.7) 
4 (30.8) 
1 (7.7) 
 
0.32 
Do you recommend that MGUS 
patients are followed-up?* 
Yes, all MGUS patients should be 
followed up frequently 
Yes, but only MGUS patients 
deemed to be at intermediate/high 
risk of progressing 
Yes, but followed-up in primary care 
No 
Missing/other 
 
 
28 (50.9) 
 
17 (30.9) 
 
 
13 (23.6) 
3 (5.5) 
1 (1.8) 
 
 
23 (56.1) 
 
12 (29.3) 
 
 
10 (24.4) 
0 
0 
 
 
5 (38.5) 
 
5 (38.5) 
 
 
3 (23.1) 
3 (23.1) 
0 
 
0.04 
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Table 2. Examples of responses to open-ended survey questions 
Question Selection of respondent answers* 
How do you describe MGUS to 
your patients? 
 You have some cells in your blood which are making a little 
too much protein.  This will probably not cause you any 
harm but you need to be followed up long-term. 
(Consultant) 
 Abnormal protein, not cancer.  Followed-up in case it 
changes and causes symptoms needing treatment. If [you] 
develop new symptoms, knowing protein present may 
speed diagnosis. (Consultant) 
 I tell some patients it is not a disease but a "pre-disease" 
state. (Consultant) 
 A protein that you don't need and in some people can 
progress into a disease that causes harm but is treatable. 
(Consultant) 
 I sometimes explain to patients that finding a paraprotein 
is a bit like finding a 'lump' and needing to investigate 
further whether benign or malignant - generally patients 
find this concept easier to understand. (Consultant) 
 An abnormal protein that in most people needs just 
watching but can start to cause damage and develop into a 
blood cancer "like  a mole we need to watch". (Registrar) 
 A sleeping condition that may or may not ever cause any 
problems/progress to myeloma. (Nurse) 
Do you tell patients that they 
have ‘MGUS’ or ‘monoclonal 
gammopathy of 
undetermined/uncertain 
signficiance’? 
 I believe most patients want to know and take some 
ownership.  Also it allows patients to educate themselves. 
(Consultant) 
 Not all patients have cognitive ability to retain complex 
info.  Some families will request limited information.  Other 
impending clinical concerns may preclude disclosure. 
(Foundation Doctor) 
 When reviewing pts I would use both of above [terms: 
MGUS and monoclonal gammopathy of undetermined 
significance] initially but then would break down and use 
words like 'blood problem', 'high level of protein' etc. 
(Foundation Doctor) 
 I usually say "abnormal protein" which comes with a long 
name "monoclonal gammopathy".  I sometimes write the 
name down.  I don't emphasise the name. (Other) 
Do you tell patients about the 
associated risk of progression 
to a haematological 
malignancy? 
 Less than I probably should. (Consultant) 
 … 10% risk.  Don't tend to say cancer or malignancy, tend 
to say "Blood Condition" or if they push it I might say "a 
type of blood cancer". (Consultant) 
 Explain small risk of progression to a malignant disease 
multiple myeloma.  They will look up on internet + find out 
or better to tell and in most cases say risk is low. 
(Consultant) 
 As part of the explanation as to why we or the GP needs to 
monitor them (Consultant) 
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 All patients should be aware of the possibility of 
progression that would mean beginning of treatment and 
not just wait and watch. (Consultant) 
 Explain the small risk of progression to symptomatic 
myeloma per year. (Registrar) 
 This will promote further understanding and acceptance of 
disease if were to happen in future. (Registrar) 
 [Responding to why they only tell some patients] Some 
elderly patients- who may become very anxious and find 
this risk quite distressing. (Specialist Nurse) 
Do you recommend follow-up 
of patients? 
 Depending on co-morbidities, haematology follow-up may 
not be needed - but annual FBC + MGUS assessment is 
reasonable - sometimes in primary care. (Consultant) 
 We see them yearly in clinic; ideally could be nurse led. 
(Registrar) 
 Can generally be f/u in primary care - unless free light 
chains only, high risk of progression, anxious patient/GP or 
complicating factors e.g. renal failure of other aetiology. 
(Registrar) 
 Frequency of attending hospital should be determined by 
stratified risk - high risk --> hospital; telephone 
clinic/community - intermediate/low. (Specialist Nurse) 
 Frequency of follow up determined by risk group for each 
patient.  Limited resource for follow up in primary care. 
(Specialist Nurse) 
 Clinic appointments create unnecessary stress to well 
patients (Nurse) 
 
 
*Quotes are displayed as presented within returned surveys unless the study team felt context was 
needed as indicated by [context]. 
 
 
 
 
 
 
 
 
